Disease · MONDO_0021661

coronary atherosclerosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. coronary atherosclerosis. Diseases, record MONDO_0021661. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021661

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: coronary atherosclerosis; Open Targets
Open Targets ID: MONDO_0021661; Open Targets
Other names: arteriosclerosis disorder of coronary artery, coronary artery arteriosclerosis (disease), coronary artery arteriosclerosis disorder; Open Targets
Disease Ontology: DOID:0061139; Disease Ontology
NCI Thesaurus: C35505; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 26 drugs, from DailyMed; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PROPRANOLOL HYDROCHLORIDE	CHEMBL1671	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ATENOLOL	CHEMBL24	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
LOVASTATIN	CHEMBL503	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PRAVASTATIN SODIUM	CHEMBL690	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
MEDROXYPROGESTERONE ACETATE	CHEMBL717	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ROSUVASTATIN	CHEMBL1496	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BEMPEDOIC ACID	CHEMBL3545313	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets37

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	5	HMG-CoA reductase inhibitor	Approval	https://conductscience.org/library/genes/3156	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	2	Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ACLY	ATP-citrate synthase	1	ATP-citrate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/47	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
BRD2	Bromodomain and extra-terminal motif (BET)	1	Bromodomain and extra-terminal motif (BET) inhibitor	Phase 2	https://conductscience.org/library/genes/6046	Drugs and targets
BRD3	Bromodomain and extra-terminal motif (BET)	1	Bromodomain and extra-terminal motif (BET) inhibitor	Phase 2	https://conductscience.org/library/genes/8019	Drugs and targets
BRD4	Bromodomain and extra-terminal motif (BET)	1	Bromodomain and extra-terminal motif (BET) inhibitor	Phase 2	https://conductscience.org/library/genes/23476	Drugs and targets
BRDT	Bromodomain and extra-terminal motif (BET)	1	Bromodomain and extra-terminal motif (BET) inhibitor	Phase 2	https://conductscience.org/library/genes/676	Drugs and targets
CETP	Cholesteryl ester transfer protein	1	Cholesteryl ester transfer protein inhibitor	Phase 3	https://conductscience.org/library/genes/1071	Drugs and targets
EDNRA	Endothelin-1 receptor	1	Endothelin receptor ET-A antagonist	Phase 2	https://conductscience.org/library/genes/1909	Drugs and targets

1 to 10 of 37

See all 37 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02624180	Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV	Phase 2	81	2021-08-19	Coronary Artery Disease, Human Immunodeficiency Virus	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT00738049	Darusentan Effect on PET Uptake Heterogeneity	Phase 2	40	2014-08-15	Coronary Artery Disease, Endothelial Dysfunction	DARUSENTAN	Its record names the disease	ClinicalTrials.gov
NCT00576576	Evaluation of Atorvastatin on Atherosclerosis Composition	Not applicable	27	2013-10-18	Atherosclerosis	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00134173	A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease	Phase 3	1,100		Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia	ATORVASTATIN, TORCETRAPIB	Its record names the disease	ClinicalTrials.gov
NCT00185042	Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease	Phase 2	534		Coronary Heart Disease	PACTIMIBE	Open Targets' reading of its record	ClinicalTrials.gov
NCT07301034	A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack	Phase 3	332		Myocardial Infarction	ZILTIVEKIMAB	Its record names the disease	ClinicalTrials.gov
NCT01067820	ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation	Phase 2	324		Coronary Artery Disease	APABETALONE	Its record names the disease	ClinicalTrials.gov
NCT00083824	Estrogen, HDL, and Coronary Heart Disease in Women	Phase 2/3	309		Cardiovascular Diseases, Coronary Disease, Heart Diseases, Coronary Arteriosclerosis	ESTROGENS, CONJUGATED, MEDROXYPROGESTERONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT07392151	Reversal to Normoglycemia by Treating Prediabetes	Phase 3	158		Prediabetes, Chronic Coronary Syndrome	DAPAGLIFLOZIN, SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT05071417	Effect Of Semaglutide In Coronary Atheroma Plaque	Phase 3	120		Atheroscleroses, Coronary	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Colchicine vs Placebo: deaths from any cause	0 of 41	0 of 38	79	NCT02624180	Trial comparisons
Colchicine vs Placebo: serious adverse events	0 of 41	2 of 38	79	NCT02624180	Trial comparisons
Group 1 vs Group 2: serious adverse events	0 of 13	0 of 7	20	NCT00738049	Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21788584	RESULT	1	PubMed
20580029	RESULT	1	PubMed
19489872	RESULT	1	PubMed
19155011	RESULT	1	PubMed
18174456	RESULT	1	PubMed
36634369	DERIVED	1	PubMed
33587443	DERIVED	1	PubMed
26385396	DERIVED	1	PubMed
23043036	DERIVED	1	PubMed
19029466	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021661

GET https://conductscience.org/api/diseases/v1/MONDO_0021661/drugs?page=2

API reference For AI assistants